Health
## Dr. Hilary Cass Firmly Advocates for Puberty Blocker Trial, Citing ‘Harm Reduction Imperative’
**LONDON, UK** – Dr. Hilary Cass, the esteemed author of the landmark independent review into gender identity services for children and young people, has issued a powerful and unequivocal call for a formal clinical trial of puberty blockers. She asserts her absolute conviction that such a trial is not merely beneficial, but essential to safeguard young patients, stating, “I am absolutely convinced that more children will be harmed if we don’t do the trial than if we do.”
Dr. Cass’s emphatic statement underscores a central finding of the comprehensive Cass Review, which highlighted significant gaps in the evidence base for medical interventions, particularly puberty-blocking hormones (GnRH analogues), for young people experiencing gender dysphoria. The review, commissioned by NHS England, meticulously scrutinised the provision of care, clinical outcomes, and the long-term effects of treatments previously offered.
Her strong advocacy for a robust clinical trial stems directly from profound concerns regarding the current lack of high-quality, long-term data on the efficacy and safety of puberty blockers in this specific population. These medications, designed to pause pubertal development, have been in use for years; however, their full impact on crucial aspects such as bone density, future fertility, cognitive and brain development, and overall psychological well-being remains insufficiently understood through rigorous, controlled study.
The absence of robust evidence means that clinicians and families currently navigate a complex landscape without the clarity needed to make fully informed decisions. A well-designed, ethical trial would aim to collect critical, long-term data on patient outcomes, enabling healthcare professionals to offer truly evidence-based care tailored to the individual needs of young people. Furthermore, it would empower adolescents and their families with a clearer, evidence-backed understanding of the potential benefits and risks, thereby facilitating genuine informed consent for such significant medical pathways.
Dr. Cass’s intervention reinforces a fundamental principle of medical ethics: that patient safety and long-term well-being must remain paramount, especially when treating vulnerable populations. Her call for a controlled trial reflects a broader, global push within the medical and scientific communities for greater scientific rigor in an evolving and highly sensitive field of medicine. Through robust and ethical research, the future direction of gender-affirming care for adolescents can be guided by sound evidence, ultimately aiming to reduce potential harm and optimize outcomes for all young people seeking support.
